Submitted by Anonymous (not verified) on 30 August 2023 - 10:56
Human medicines European public assessment report (EPAR): Qinlock, ripretinib, Gastrointestinal Stromal Tumors, Date of authorisation: 18/11/2021, Revision: 5, Status: Authorised
Source: